Hangzhou Tigermed Consulting Co., Ltd.
Recent events
Recent events tied to this brand in public sources.
Back to profile6 entries
2021
Adlai Nortye completes $100 million Series D financing
Adlai Nortye announced that it completed a $100 million Series D financing round co-led by SDIC Fund Management and Tigermed, with proceeds intended to support drug development and portfolio expansion.
2020
Heji Pharmaceutical completes Series A funding
Heji Pharmaceutical announced that it completed a 280 million yuan Series A financing, with Baitai Pharma, Hisun Pharmaceutical, Tigermed, and Pucheng Investment among the investors.
2020
Tigermed begins Hong Kong IPO offering
Hangzhou Tigermed announced that its Hong Kong IPO subscription began on July 28, 2020, with a planned listing on August 7.
2020
Yahong Medicine completes Series C+ funding
Yahong Medicine announced that it had completed its Series C+ funding round. The funds will support existing pipeline products and preparations for commercialization of new products.
2020
WEN CHEN resigns as Tigermed deputy general manager
Hangzhou Tigermed Consulting Co., Ltd. announced that deputy general manager WEN CHEN resigned for personal reasons and would hold no further position at the company.
2020
Canbridge Pharmaceuticals completes US$98 million Series D financing
Canbridge Pharmaceuticals announced that it had completed a US$98 million Series D financing. General Atlantic and WuXi AppTec led the round, and each had the right to make an additional investment of up to US$10 million subject to agreed conditions.